Osteoarthritis and Diabetes: Where Are We and Where Should We Go?

被引:12
|
作者
Alenazi, Aqeel M. [1 ]
Alhowimel, Ahmed S. [1 ]
Alshehri, Mohammed M. [2 ]
Alqahtani, Bader A. [1 ]
Alhwoaimel, Norah A. [1 ]
Segal, Neil A. [3 ]
Kluding, Patricia M. [4 ]
机构
[1] Prince Sattam Bin Abdulaziz Univ, Dept Hlth & Rehabil Sci, Alkharj 11942, Saudi Arabia
[2] Jazan Univ, Dept Phys Therapy, Jazan 45142, Saudi Arabia
[3] Univ Kansas, Dept Phys Med & Rehabil, Med Ctr, Kansas City, KS 66160 USA
[4] Univ Kansas, Dept Phys Therapy & Rehabil Sci, Med Ctr, Kansas City, KS 66160 USA
关键词
osteoarthritis; diabetics; high blood glucose; pain intensity; symptoms; gait; pace; RADIOGRAPHIC KNEE OSTEOARTHRITIS; EARLY POSTOPERATIVE OUTCOMES; CLINICALLY DIAGNOSED KNEE; HAND OSTEOARTHRITIS; RISK-FACTORS; METABOLIC SYNDROME; GENERALIZED OSTEOARTHRITIS; UNITED-STATES; WALKING SPEED; ASSOCIATION;
D O I
10.3390/diagnostics13081386
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Diabetes mellitus (DM) and osteoarthritis (OA) are chronic noncommunicable diseases that affect millions of people worldwide. OA and DM are prevalent worldwide and associated with chronic pain and disability. Evidence suggests that DM and OA coexist within the same population. The coexistence of DM in patients with OA has been linked to the development and progression of the disease. Furthermore, DM is associated with a greater degree of osteoarthritic pain. Numerous risk factors are common to both DM and OA. Age, sex, race, and metabolic diseases (e.g., obesity, hypertension, and dyslipidemia) have been identified as risk factors. These risk factors (demographics and metabolic disorder) are associated with DM or OA. Other possible factors may include sleep disorders and depression. Medications for metabolic syndromes might be related to the incidence and progression of OA, with conflicting results. Given the growing body of evidence indicating a relationship between DM and OA, it is vital to analyze, interpret, and integrate these findings. Therefore, the purpose of this review was to evaluate the evidence on the prevalence, relationship, pain, and risk factors of both DM and OA. The research was limited to knee, hip, and hand OA.
引用
收藏
页数:19
相关论文
共 50 条
  • [21] The gut microbiota in osteoarthritis: where do we stand and what can we do?
    Hao, Xiaoxia
    Shang, Xingru
    Liu, Jiawei
    Chi, Ruimin
    Zhang, Jiaming
    Xu, Tao
    ARTHRITIS RESEARCH & THERAPY, 2021, 23 (01)
  • [22] Epidemiology of Hepatocellular Carcinoma in the United States: Where Are We? Where Do We Go?
    El-Serag, Hashem B.
    Kanwal, Fasiha
    HEPATOLOGY, 2014, 60 (05) : 1767 - 1775
  • [23] Occupational Rhinitis and Asthma: Where Do We Stand, Where Do We Go?
    Castano, Roberto
    Malo, Jean-Luc
    CURRENT ALLERGY AND ASTHMA REPORTS, 2010, 10 (02) : 135 - 142
  • [24] Neonatal abstinence syndrome: where are we, and where do we go from here?
    Brandt, Laura
    Finnegan, Loretta P.
    CURRENT OPINION IN PSYCHIATRY, 2017, 30 (04) : 268 - 274
  • [25] Occupational Rhinitis and Asthma: Where Do We Stand, Where Do We Go?
    Roberto Castano
    Jean-Luc Malo
    Current Allergy and Asthma Reports, 2010, 10 : 135 - 142
  • [26] Vaccine Hesitancy: Where We Are and Where We Are Going
    McClure, Catherine C.
    Cataldi, Jessica R.
    O'Leary, Sean T.
    CLINICAL THERAPEUTICS, 2017, 39 (08) : 1550 - 1562
  • [27] Air travel and thromboembolic events after orthopedic surgery: Where are we and where do we need to go?
    Donnally, Chester J., III
    Rosas, Samuel
    Sheu, Jonathan I.
    Damodar, Dhanur
    Buller, Leonard T.
    Cohen-Levy, Wayne B.
    Hernandez, Francisco J.
    Hernandez, Victor H.
    JOURNAL OF TRANSPORT & HEALTH, 2018, 8 : 100 - 105
  • [28] Tackling adolescent substance abuse in Hong Kong: Where we should and should not go
    Shek, Daniel T. L.
    THESCIENTIFICWORLDJOURNAL, 2007, 7 : 2021 - 2030
  • [29] Cardiovascular Disease in Children and Adolescents with Diabetes: Where Are We, and Where Are We Going?
    Truong, Uyen T.
    Maahs, David M.
    Daniels, Stephen R.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2012, 14 : S11 - S21
  • [30] Medication Risk Communication in Rheumatology: Where Are We and Where Do We Go from Here?
    Blalock, Susan J.
    CURRENT RHEUMATOLOGY REPORTS, 2017, 19 (02)